MDT · XBRL financial data

Medtronic financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MDT's year ends in late April)

In millions of dollars	FY 2021Apr 30, 2021	FY 2022Apr 29, 2022	FY 2023Apr 28, 2023	FY 2024Apr 26, 2024	FY 2025Apr 25, 2025	FY 2026Apr 24, 2026
Revenue from contracts with customers	30,117	31,686	31,227	32,364	33,537	36,364
Cost of goods and services sold	10,483	10,145	10,719	11,216	11,632	12,721
Selling, general and administrative	10,148	10,292	10,415	10,736	10,849	11,784
Other operating income (expense)	(315)	(862)	131	(464)	23	(386)
Operating income (loss)	4,484	5,752	5,485	5,144	5,955	6,467
Interest expense	925	553	636	719	729	715
Other income (expense)	336	318	515	412	402	384
Income tax expense (benefit)	265	456	1,580	1,133	936	1,299
Net income (loss)	3,606	5,039	3,758	3,676	4,662	4,801
Earnings per share, basic USD per share	2.68	3.75	2.83	2.77	3.63	3.75
Earnings per share, diluted USD per share	2.66	3.73	2.82	2.76	3.61	3.73
Weighted average shares, basic millions of shares	1,345	1,342	1,330	1,328	1,286	1,282
Weighted average shares, diluted millions of shares	1,354	1,351	1,333	1,330	1,290	1,288

Fiscal years (MDT's year ends in late April)

In millions of dollars	FY 2021Apr 30, 2021	FY 2022Apr 29, 2022	FY 2023Apr 28, 2023	FY 2024Apr 26, 2024	FY 2025Apr 25, 2025	FY 2026Apr 24, 2026
Cash and cash equivalents	3,593	3,714	1,543	1,284	2,218	1,949
Short-term investments	7,224	6,859	6,416	6,721	6,747	7,271
Accounts receivable	5,462	5,551	5,998	6,128	6,515	6,643
Inventory	4,313	4,616	5,293	5,217	5,476	5,951
Total current assets	22,548	23,059	21,675	21,935	23,814	24,787
Property and equipment, net	5,221	5,413	5,569	6,131	6,837	7,417
Right-of-use asset	998	854	1,041	1,012	1,100	1,197
Goodwill	41,961	40,502	41,425	40,986	41,737	42,587
Total assets	93,083	90,981	90,948	89,981	91,680	93,028
Accounts payable	2,106	2,276	2,662	2,410	2,449	2,644
Commercial paper	—	—	0	1,073	0	—
Total current liabilities	8,509	12,394	9,051	10,789	12,879	11,658
Lease liability, non-current	829	703	869	840	918	989
Total liabilities	41,481	38,260	39,283	39,561	43,424	42,956
Retained earnings	28,594	30,250	30,392	30,403	31,476	32,638
Total stockholders' equity	51,428	52,551	51,483	50,214	48,024	49,463
Total liabilities and equity	93,083	90,981	90,948	89,981	91,680	93,028
Common shares outstanding (cover page) millions of shares	1,344	1,329	1,330	1,282	1,281	1,280

Fiscal years (MDT's year ends in late April)

In millions of dollars	FY 2021Apr 30, 2021	FY 2022Apr 29, 2022	FY 2023Apr 28, 2023	FY 2024Apr 26, 2024	FY 2025Apr 25, 2025	FY 2026Apr 24, 2026
Net income (loss)	3,606	5,039	3,758	3,676	4,662	4,801
Stock-based compensation	344	359	355	393	429	457
Depreciation and amortization	2,702	2,707	2,697	2,647	2,861	2,958
Net cash from operating activities	6,240	7,346	6,039	6,787	7,044	7,330
Purchases of property and equipment	1,355	1,368	1,459	1,587	1,859	1,904
Net cash from investing activities	(2,866)	(1,659)	(3,493)	(2,366)	(1,937)	(2,934)
Proceeds from issuing common stock	—	—	—	284	508	516
Proceeds from issuing equity	474	429	308	284	508	—
Share repurchases	652	2,544	645	2,138	3,235	1,035
Dividends paid	3,120	3,383	3,616	3,666	3,589	3,639
Proceeds from long-term debt	7,172	0	5,409	0	3,209	1,747
Repayments of long-term debt	7,367	1	6,012	0	0	2,930
Net cash from financing activities	(4,136)	(5,336)	(4,960)	(4,450)	(4,361)	(4,751)
Net change in cash	(547)	121	(2,171)	(259)	934	(269)

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Medtronic	1,691	9,756	1,793	1.3B	Q1 FY27 10-QJul 31, 2026
Stryker	3,271	6,520	1,461*	380.7M	Q3 FY26 10-QSep 30, 2026
Boston Scientific	609	5,138	1,048*	1.4B	Q3 FY26 10-QSep 30, 2026
3M	4,835	6,584	486*	516.7M	Q3 FY26 10-QSep 30, 2026
Intuitive Surgical	2,978	3,049	1,224*	346.6M	Q3 FY26 10-QSep 30, 2026
Becton Dickinson	708	4,983	not reported	272.4M	Q3 FY26 10-QJun 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	Q2 FY26 10-QJun 30, 2026
Resmed	1,011	1,415	422	140.7M	Q1 FY27 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.